On September 22, 2016 Xenetic Biosciences, Inc. (OTCQB: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, reported that Scott Maguire, CEO of Xenetic Biosciences, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 3:30 p.m. ET in New York at the Sofitel New York (Press release, Xenetic Biosciences, SEP 22, 2016, View Source [SID1234537812]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During his presentation, Mr. Maguire will provide a corporate update and discuss the Company’s clinical and regulatory strategies for its product candidates currently in development in-house and with Xenetic’s biotechnology and pharmaceutical partners. The Company’s product pipeline currently includes Virexxa (sodium cridanimod), which is being evaluated for the treatment of endometrial cancer and triple negative breast cancer, ErepoXen, a polysialylated form of erythropoietin (EPO), a hormone produced by the kidneys to maintain red blood cell production and prevent anemia, and OncoHist, which is being evaluated for the treatment of acute myeloid leukemia (AML) in refractory patients and refractory non-Hodgkin lymphoma (NHL).
Mr. Maguire will also discuss Xenetic’s $100 million license deal with Shire and provide an overview of the product candidate and clinical status.
A live webcast of the presentation will be available by accessing the IR Calendar in the Investors section of the Xenetic website (www.xeneticbio.com). The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.